Name:
BZ_2022_Q3_Labcorp ITZ_research regulations video
Description:
BZ_2022_Q3_Labcorp ITZ_research regulations video
Thumbnail URL:
https://cadmoremediastorage.blob.core.windows.net/07576268-bec3-4509-93ac-a6d1face50ed/videoscrubberimages/Scrubber_6.jpg
Duration:
T00H01M21S
Embed URL:
https://stream.cadmore.media/player/07576268-bec3-4509-93ac-a6d1face50ed
Content URL:
https://cadmoreoriginalmedia.blob.core.windows.net/07576268-bec3-4509-93ac-a6d1face50ed/Labcorp ITZ video - V1.mp4?sv=2019-02-02&sr=c&sig=1O1qqChx6xfB6fUwAUptaj5NvIRMYjbdxUlbTnpZOh0%3D&st=2024-11-21T13%3A19%3A19Z&se=2024-11-21T15%3A24%3A19Z&sp=r
Upload Date:
2022-11-03T00:00:00.0000000
Transcript:
Language: EN.
Segment:0 .
[MUSIC PLAYING]
SPEAKER: Many agencies rely on manual data provided by both sponsors and health authorities in order to process drug applications, which can lead to significant delays in the speed that novel therapeutics become available to patients. Supporting new drug application submissions using manual data will become increasingly obsolete as electronic versions can offer increased efficiency, traceability, and data preservation while simultaneously providing a comprehensive audit trail for companies navigating the drug development continuum.
SPEAKER: The National Medical Products Administration, the Chinese agency for regulating drugs and medical devices, have already taken steps to digitalize applications through the development of the electronic regulated product submission system. Learn how Labcorp bioanalytical services has navigated the manual to electronic workbook transition in China to achieve NMPA approval for bioanalytical data submissions in 2022.
SPEAKER: [MUSIC PLAYING]